(Q43869754)

English

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

0 references

8

object named as

Eric Winer

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

7

object named as

Lauri Welles

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

Lyndsay Harris

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Gerald Batist

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Robert Belt

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Douglas Rovira

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Rudolph Navari

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Nozar Azarnia

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

TLC D-99 Study Group

9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

0 references

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

25-36

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

21 January 2018

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10201

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10201

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43869754&oldid=2117189705"